AAAAAA
Results:
1-13
|
Results: 13
Authors:
van Acker, FAA
Boven, E
Kramer, K
Haenen, GRMM
Bast, A
van der Vijgh, WJF
Citation: Faa. Van Acker et al., Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity, CLIN CANC R, 7(5), 2001, pp. 1378-1384
Authors:
Houba, PHJ
Boven, E
van der Meulen-Muileman, IH
Leenders, RGG
Scheeren, JW
Pinedo, HM
Haisma, HJ
Citation: Phj. Houba et al., Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate, INT J CANC, 91(4), 2001, pp. 550-554
Authors:
Houba, PHJ
Boven, E
van der Meulen-Muileman, IH
Leenders, RGG
Scheeren, JW
Pinedo, HM
Haisma, HJ
Citation: Phj. Houba et al., A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer, BR J CANC, 84(4), 2001, pp. 550-557
Authors:
Batra, S
Larsson, I
Boven, E
Citation: S. Batra et al., Mitochondrial and microsomal peripheral benzodiazepine receptors in human ovarian cancer xenografts, INT J MOL M, 5(6), 2000, pp. 619-623
Authors:
Kolfschoten, GM
Pinedo, HM
Scheffer, PG
Schluper, HMM
Erkelens, CAM
Boven, E
Citation: Gm. Kolfschoten et al., Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system, GYNECOL ONC, 76(3), 2000, pp. 362-368
Authors:
Van Hattum, AH
Pinedo, HM
Schluper, HMM
Hausheer, FH
Boven, E
Citation: Ah. Van Hattum et al., New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer, INT J CANC, 88(2), 2000, pp. 260-266
Authors:
Kolfschoten, GM
Hulscher, TM
Pinedo, HM
Boven, E
Citation: Gm. Kolfschoten et al., Drug resistance features and S-phase fraction as possible determinants fordrug response in a panel of human ovarian cancer xenografts, BR J CANC, 83(7), 2000, pp. 921-927
Authors:
Welink, J
Boven, E
Vermorken, JB
Gall, HE
van der Vijgh, WJF
Citation: J. Welink et al., Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal or liverfunction, CLIN CANC R, 5(9), 1999, pp. 2349-2358
Authors:
Leenders, RGG
Damen, EWP
Bijsterveld, EJA
Scheeren, HW
Houba, PHJ
van der Meulen-Muileman, IH
Boven, E
Haisma, HJ
Citation: Rgg. Leenders et al., Novel anthracycline-spacer-beta-glucuronide, -beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy, BIO MED CH, 7(8), 1999, pp. 1597-1610
Authors:
Boven, E
Jansen, WJM
Hulscher, TM
Beijnen, JH
van Tellingen, O
Citation: E. Boven et al., The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts, EUR J CANC, 35(5), 1999, pp. 840-849
Authors:
Houba, PHJ
Boven, E
van der Meulen-Muileman, IH
Leenders, RGG
Scheeren, JW
Pinedo, HM
Haisma, HJ
Citation: Phj. Houba et al., Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts, BIOCH PHARM, 57(6), 1999, pp. 673-680
Authors:
Boven, E
Pinedo, HM
van Hattum, AH
Scheffer, PG
Peters, WHM
Erkelens, CAM
Schluper, HMM
Kuiper, CM
van Ark-Otte, J
Giaccone, G
Citation: E. Boven et al., Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening, BR J CANC, 78(12), 1998, pp. 1586-1593
Authors:
Houba, PHJ
Boven, E
Erkelens, CAM
Leenders, RGG
Scheeren, JW
Pinedo, HM
Haisma, HJ
Citation: Phj. Houba et al., The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts, BR J CANC, 78(12), 1998, pp. 1600-1606
Risultati:
1-13
|